SUNNYVALE, CA--(Marketwire - October 28, 2009) - Arrayit Corporation (OTCBB: ARYC) today announced the sale of a system to the Center of Excellence for Nucleic Acid-Based Technologies (CENAT) in Poznan, Poland. The Arrayit NanoPrint Microarrayer will be used by CENAT for scientific and medical collaborations throughout the prosperous democracy.
"We are very excited to have CENAT as a customer for our NanoPrint enterprise level microarray robot," stated Rene Schena, CEO and Chairman of Arrayit. "This relationship demonstrates the commercial value of our core technology for cancer research and diagnostics."
"The Arrayit microarray manufacturing platform will help accelerate on-going myeloid leukemia cancer analysis at CENAT," stated Dr. Luiza Handschuh, CENAT Laboratory Director. "Arrayit's system offers us the ability to make high quality microarrays of all types that will greatly enhance cancer research by enabling quantitative DNA, RNA and protein analysis."
Versatile NanoPrint microarrayers have also been installed at other major research and diagnostics centers including Harvard University in Massachusetts, Sandia National Laboratories in New Mexico, Scripps Research Institute in Florida, The Biodesign Institute in Arizona, and Mount Sinai School of Medicine in New York City.
About Arrayit Corporation
Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. It now offers over 650 products to a customer base, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises. Please visit www.arrayit.com for more information.
Safe Harbor Statement
Except for historical information contained herein, statements made in this
release that constitute forward-looking statements are based on currently
available information, involve certain risks and uncertainties and the
Company assumes no responsibility to update any such forward-looking
statement. The following factors, among others, may cause actual results to
differ materially from the results suggested in the forward-looking
statements. Risks that may result from changes in the Company's business
operations; our ability to keep pace with technological advances;
significant competition in the biomedical business; our relationships with
key suppliers and customers; quality and consumer acceptance of newly
introduced products; market volatility; non-availability of product; excess
inventory; price and product competition; new product introductions, the
outcome of our legal disputes; the possibility that the review of our prior
filings by the SEC may result in changes to our financial statements; and
the possibility that stockholders or regulatory authorities may initiate
proceedings against Arrayit and/or our officers and directors as a result
of any restatements. Risk factors
associated with our business, including some of the facts set forth
herein, are detailed in the Company's Form 10-K/A for the fiscal year ended
December 31, 2008 and Form 10-Q/A for the fiscal first quarter ended March
31, 2009 and Form 10-Q/A for the fiscal third quarter ended September 30,
2008.
